TY - JOUR
T1 - Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study
AU - Iovino, Claudio
AU - Peiretti, Enrico
AU - Tatti, Filippo
AU - Querques, Giuseppe
AU - Borrelli, Enrico
AU - Sacconi, Riccardo
AU - Chhablani, Jay
AU - Agrawal, Hitesh
AU - Boon, Camiel J. F.
AU - van Dijk, Elon H. C.
AU - Cennamo, Gilda
AU - Lupidi, Marco
AU - Muzi, Alessio
AU - di Iorio, Valentina
AU - Iglicki, Matias
AU - Smadar, Lital
AU - Loewenstein, Anat
AU - Zur, Dinah
N1 - Publisher Copyright: © 2021, The Author(s), under exclusive licence to The Royal College of Ophthalmologists. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Background: To investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT). Methods: A total of 25 eyes from 23 patients with PPS treated with PDT were retrospectively evaluated in this multicentric study. Main outcome measure was the proportion of eyes that achieved treatment success, defined as a decrease in both subretinal fluid (SRF) height and central subfield thickness (CST), at 3 months after PDT compared to baseline. Secondary outcomes were the change in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment and predictive factors for treatment success. When available, data between 3 and 12 months were also reviewed. Results: Treatment success was achieved in 16 eyes (64%). In the total cohort, CST decreased significantly from 356 ± 118 µm at baseline to 282 ± 90 µm and 270 ± 91 µm at 1 and 3 months, respectively (p < 0.001). Maximal SRF height decreased significantly from 102 ± 83 µm at baseline to 38 ± 46 µm and 32 ± 42 µm at 1 and 3 months, respectively (p < 0.001), and remained stable at month 6 (29 ± 44 µm) and month 12 (23 ± 35 µm). BCVA improved significantly from baseline to month 3 (p = 0.021). Conclusions: PDT can be considered an efficacious treatment option in patients with PPS. Prospective data with longer follow-up in a bigger cohort are needed in order to determine the optimal treatment algorithm in this relatively novel disease.
AB - Background: To investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT). Methods: A total of 25 eyes from 23 patients with PPS treated with PDT were retrospectively evaluated in this multicentric study. Main outcome measure was the proportion of eyes that achieved treatment success, defined as a decrease in both subretinal fluid (SRF) height and central subfield thickness (CST), at 3 months after PDT compared to baseline. Secondary outcomes were the change in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment and predictive factors for treatment success. When available, data between 3 and 12 months were also reviewed. Results: Treatment success was achieved in 16 eyes (64%). In the total cohort, CST decreased significantly from 356 ± 118 µm at baseline to 282 ± 90 µm and 270 ± 91 µm at 1 and 3 months, respectively (p < 0.001). Maximal SRF height decreased significantly from 102 ± 83 µm at baseline to 38 ± 46 µm and 32 ± 42 µm at 1 and 3 months, respectively (p < 0.001), and remained stable at month 6 (29 ± 44 µm) and month 12 (23 ± 35 µm). BCVA improved significantly from baseline to month 3 (p = 0.021). Conclusions: PDT can be considered an efficacious treatment option in patients with PPS. Prospective data with longer follow-up in a bigger cohort are needed in order to determine the optimal treatment algorithm in this relatively novel disease.
UR - http://www.scopus.com/inward/record.url?scp=85103666047&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41433-021-01515-z
DO - https://doi.org/10.1038/s41433-021-01515-z
M3 - Article
C2 - 33824506
SN - 0950-222X
JO - Eye (London, England)
JF - Eye (London, England)
ER -